Chugai aims to offer Actemra for COVID-19 in Japan

9 February 2021
chugai-large

Chugai Pharmaceuticals (TYO: 4519) has announced results from the Phase III J-COVACTA study of Actemra (tocilizumab) as a treatment for coronavirus patients with pneumonia.

The data show that after four weeks, 72.9% of people in the single-arm study could be discharged from the hospital.

81.3% improved in at least one category on the 7-Category Ordinal scale, the primary endpoint of the study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology